Sandoz Group AG (XSWX:SDZ) Insider Ownership : 0.00 % (As of Nov. 10, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sandoz Group AG's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sandoz Group AG's Institutional Ownership is 39.37%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sandoz Group AG's Float Percentage Of Total Shares Outstanding is 0.00%.

Sandoz Group AG Insider Ownership Historical Data

The historical data trend for Sandoz Group AG's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Insider Ownership Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Insider Ownership

Sandoz Group AG Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24
Insider Ownership	-	-	-	-

Sandoz Group AG Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Sandoz Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (XSWX:SDZ) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZNY:USA SDZz:UK 0SAN:UK D8Y0:Germany

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines